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Cost of run of new drug to the market increased dramatically last decade and tend to be 2-3 
billion of US dollars. At the same time there are thousands of approved drugs at the market which 
passed safety preclinical and clinical trial. Drug repositioning of approved drugs for new indications 
looks attractive due to giving a chance to speed up and decrease cost to market. 
Actual master class will guide through in silico workflow in drug repositioning using the 
biggest comercial avalible data bases Pathway Studio (biomolecular objects and relations) Reaxys 
Medicinal Chemistry (bioactive moleculas, targets, biological properties of moleculas). 
Workflow 1 will help to find new potential indications and score them for known drug using 
Pathway Studio. It start from particular drug and it’s main targets. 
Workflow 2 start from particular disease including rare disease, seek known targets for the 
disease using Pathway Studio. As a next step Reaxys Medicinal Chemistry will help to find all 
inhibitors targets found. The molucelas would be filtered to have apropriate affinity to the targets, to 
pass at least I phase of clinical trails, to have Mw ≤ 400, LogP ≤5, Hydrogen bond donor ≤3, 
Hydrogen bond acceptor ≤7. Additional information about action of molecules would be collected 
using Pathway Studio. Example of the results is shown on figure 1. 
 
Figure 1. Humira indications reported in clinical trials and biomedical literature as found in 
Pathway Studio database and annotated in Pathway Studio interface 
 
